← FDA DRUG APPROVALS

FDA ANDA · ANDA211953

LABETALOL HYDROCHLORIDE

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA211953
TYPE
ANDA
ORIGINAL APPROVAL
2021-08-18
LATEST ACTION
2025-06-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LABETALOL HYDROCHLORIDEPrescription
LABETALOL HYDROCHLORIDE 300MG · TABLET · ORAL
LABETALOL HYDROCHLORIDEPrescription
LABETALOL HYDROCHLORIDE 100MG · TABLET · ORAL
LABETALOL HYDROCHLORIDEPrescription
LABETALOL HYDROCHLORIDE 200MG · TABLET · ORAL

Approval history

2025-06-06Manufacturing (CMC) · Supplement 12 · unknownAP
2025-05-07Labeling · Supplement 7 · standardAP
2021-08-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →